These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20167481)

  • 1. Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
    Lesuisse D; Dutruc-Rosset G; Tiraboschi G; Dreyer MK; Maignan S; Chevalier A; Halley F; Bertrand P; Burgevin MC; Quarteronet D; Rooney T
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1985-9. PubMed ID: 20167481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design.
    Zhang N; Zhong R; Yan H; Jiang Y
    Chem Biol Drug Des; 2011 Mar; 77(3):199-205. PubMed ID: 21244636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines.
    Ma XH; Wang R; Tan CY; Jiang YY; Lu T; Rao HB; Li XY; Go ML; Low BC; Chen YZ
    Mol Pharm; 2010 Oct; 7(5):1545-60. PubMed ID: 20712327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
    Lee J; Kim KH; Jeong S
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
    Canduri F; Uchoa HB; de Azevedo WF
    Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
    Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
    Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
    Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
    Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
    Vulpetti A; Crivori P; Cameron A; Bertrand J; Brasca MG; D'Alessio R; Pevarello P
    J Chem Inf Model; 2005; 45(5):1282-90. PubMed ID: 16180905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N; Bharatam PV
    Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives.
    Pande V; Ramos MJ
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5129-35. PubMed ID: 16213715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.
    Vandromme L; Piguel S; Lozach O; Meijer L; Legraverend M; Grierson DS
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3144-6. PubMed ID: 16616489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
    Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
    Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β.
    Pradeep H; Rajanikant GK
    Mol Divers; 2012 Aug; 16(3):553-62. PubMed ID: 22918724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.
    Lesuisse D; Tiraboschi G; Krick A; Abecassis PY; Dutruc-Rosset G; Babin D; Halley F; Châtreau F; Lachaud S; Chevalier A; Quarteronet D; Burgevin MC; Amara C; Bertrand P; Rooney T
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2344-9. PubMed ID: 20189807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
    Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
    J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
    Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
    J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta.
    Arnost M; Pierce A; ter Haar E; Lauffer D; Madden J; Tanner K; Green J
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1661-4. PubMed ID: 20138514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.